TY - JOUR T1 - Pharmacogenetic Analysis of Liver Toxicity after Busulfan/Cyclophosphamide-based Allogeneic Hematopoietic Stem Cell Transplantation JF - Anticancer Research JO - Anticancer Res SP - 4377 LP - 4380 VL - 27 IS - 6C AU - ERAY GOEKKURT AU - JAN STOEHLMACHER AU - CHRISTIAN STUEBER AU - CHRISTINE WOLSCHKE AU - THOMAS EIERMANN AU - SIMONA IACOBELLI AU - AXEL R. ZANDER AU - GERHARD EHNINGER AU - NICOLAUS KRÖGER Y1 - 2007/11/01 UR - http://ar.iiarjournals.org/content/27/6C/4377.abstract N2 - The aim of this study was to evaluate the impact of genomic polymorphisms of methylene-tetrahydrofolate-reductase (MTHFR-C677T, MTHFR-A1298C) and various glutathione S-transferases (GSTP1-Ile105Val, GSTA1*a/b, GSTM1, GSTT1) on the occurrence of liver toxicity in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Patients and Methods: Eighty-four adult patients were enrolled in this retrospective study. All patients were treated with busulfan/cyclophosphamide as a conditioning regimen and received cyclosporine and short-course MTX for GvHD prophylaxis. Genotyping was performed using PCR based restriction-fragment-length-polymorphism (RFLP) techniques. Results: Multivariate analysis identified the MTHFR-A1298C polymorphism as an independent predictor for maximum levels of bilirubin (p=0.0025) and duration of hyperbilirubinaemia (p=0.013). Furthermore, there was an association between this polymorphism and the occurrence of the sinusoidal obstruction syndrome (SOS) (p=0.048). No significant associations between the MTHFR-C677T or the various GST polymorphisms and liver toxicity were observed. Conclusion: The MTHFR-A1298C polymorphism might be associated with liver toxicity in patients receiving allogeneic HSCT. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -